دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Vitamin K and osteoarthritis: is there a link?
Richard F Loeser, Francis Berenbaum, Margreet Kloppenburg
doi : 10.1136/annrheumdis-2020-219765
Annals of the Rheumatic Diseases 2021;80:547-549.
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger
doi : 10.1136/annrheumdis-2020-219174
Annals of the Rheumatic Diseases 2021;80:550-557.
The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions.
Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci
Eunji Ha, Sang-Cheol Bae, Kwangwoo Kim
doi : 10.1136/annrheumdis-2020-219065
Annals of the Rheumatic Diseases 2021;80:558-565.
Objectives Nearly 110 susceptibility loci for rheumatoid arthritis (RA) with modest effect sizes have been identified by population-based genetic association studies, suggesting a large number of undiscovered variants behind a highly polygenic genetic architecture of RA. Here, we performed the largest-ever trans-ancestral meta-analysis with the aim to identify new RA loci and to better understand RA biology underlying genetic associations.
Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis
Joshua F Baker, Bryant R England, Michael George, Grant Cannon, Brian Sauer, Alexis Ogdie, Bartlett C Hamilton, Carlos Hunter, Michael J Duryee, Geoffrey Thiele, Ted R Mikuls
doi : 10.1136/annrheumdis-2020-219140
Annals of the Rheumatic Diseases 2021;80:566-572.
Purpose Rheumatoid arthritis (RA) is associated with a higher risk of diabetes mellitus (DM). Our aim was to determine associations between inflammatory disease activity (including evaluation of specific cytokines and chemokines) and incident DM.
Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice
Rabia Moentadj, Yiwen Wang, Kate Bowerman, Linda Rehaume, Hendrik Nel, Paraic O Cuiv, Juliette Stephens, Amalina Baharom, Muralidhara Maradana, Vanessa Lakis, Mark Morrison, Timothy Wells, Philip Hugenholtz, Helen Benham, Kim-Anh Le Cao, Ranjeny Thomas
doi : 10.1136/annrheumdis-2020-219009
Annals of the Rheumatic Diseases 2021;80:573-581.
Objectives Analysis of oral dysbiosis in individuals sharing genetic and environmental risk factors with rheumatoid arthritis (RA) patients may illuminate how microbiota contribute to disease susceptibility. We studied the oral microbiota in a prospective cohort of patients with RA, first-degree relatives (FDR) and healthy controls (HC), then genomically and functionally characterised streptococcal species from each group to understand their potential contribution to RA development.
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C Coates
doi : 10.1136/annrheumdis-2020-218808
Annals of the Rheumatic Diseases 2021;80:582-590.
Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA).
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
Alessandra Nerviani, Marie-Astrid Boutet, Wang Sin Gina Tan, Katriona Goldmann, Nirupam Purkayastha, Tamas Ajtos Lajtos, Rebecca Hands, Myles Lewis, Stephen Kelly, Costantino Pitzalis
doi : 10.1136/annrheumdis-2020-218186
Annals of the Rheumatic Diseases 2021;80:591-597.
Objectives To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.
Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis
Cindy G Boer, Ingrid Szilagyi, N Long Nguyen, Tuhina Neogi, Ingrid Meulenbelt, M Arfan Ikram, André G Uitterlinden, Sita Bierma-Zeinstra, Bruno H Stricker, Joyce B van Meurs
doi : 10.1136/annrheumdis-2020-219483
Annals of the Rheumatic Diseases 2021;80:598-604.
Objectives Vitamin K is hypothesised to play a role in osteoarthritis (OA) pathogenesis through effects on vitamin K-dependent bone and cartilage proteins, and therefore may represent a modifiable risk factor. A genetic variant in a vitamin K-dependent protein that is an essential inhibitor for cartilage calcification, matrix Gla protein (MGP), was associated with an increased risk for OA. Vitamin K antagonist anticoagulants (VKAs), such as warfarin and acenocoumarol, act as anticoagulants through inhibition of vitamin K-dependent blood coagulation proteins. VKAs likely also affect the functioning of other vitamin K-dependent proteins such as MGP.
Warfarin use and risk of knee and hip replacements
Priyanka Ballal, Christine Peloquin, Cindy Germaine Boer, Tuhina Neogi
doi : 10.1136/annrheumdis-2020-219646
Annals of the Rheumatic Diseases 2021;80:605-609.
Background Identification of modifiable risk factors and treatments for osteoarthritis (OA) are needed. Warfarin, a vitamin K antagonist, causes fetal and animal model skeletal abnormalities. Vitamin K insufficiency has been associated with OA, but whether warfarin is also detrimental to OA is not known.
Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis
Matej Sapina, Marijan Frkovic, Mario Sestan, Sasa Srsen, Aleksandar Ovuka, Mateja Batnozic Varga, Karolina Kramaric, Dario Brdaric, Kresimir Milas, Alenka Gagro, Marija Jelusic
doi : 10.1136/annrheumdis-2020-218649
Annals of the Rheumatic Diseases 2021;80:610-616.
Objectives Research on spatial variability of the incidence of IgA vasculitis (IgAV) in children and its potential implications for elucidation of the multifactorial aetiology and pathogenesis is limited. We intended to observe spatial variability of the incidence of IgAV and IgA vasculitis-associated nephritis (IgAVN) using modern geostatistical methods, and hypothesised that their spatial distribution may be spatially clustered.
Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-? hyper-responsiveness and risk for macrophage activation syndrome
Grant S Schulert, Alex V Pickering, Thuy Do, Sanjeev Dhakal, Ndate Fall, Daniel Schnell, Mario Medvedovic, Nathan Salomonis, Sherry Thornton, Alexei A Grom
doi : 10.1136/annrheumdis-2020-217470
Annals of the Rheumatic Diseases 2021;80:617-625.
Objectives Systemic juvenile idiopathic arthritis (SJIA) confers high risk for macrophage activation syndrome (MAS), a life-threatening cytokine storm driven by interferon (IFN)-?. SJIA monocytes display IFN-? hyper-responsiveness, but the molecular basis of this remains unclear. The objective of this study is to identify circulating monocyte and bone marrow macrophage (BMM) polarisation phenotypes in SJIA including molecular features contributing to IFN response.
Association of novel rare coding variants with juvenile idiopathic arthritis
Xinyi Meng, Xiaoyuan Hou, Ping Wang, Joseph T Glessner, Hui-Qi Qu, Michael E March, Sipeng Zhang, Xiaohui Qi, Chonggui Zhu, Kenny Nguyen, Xinyi Gao, Xiaoge Li, Yichuan Liu, Wentao Zhou, Shuyue Zhang, Junyi Li, Yan Sun, Jie Yang, Patrick M A Sleiman, Qianghua Xia, Hakon Hakonarson, Jin Li
doi : 10.1136/annrheumdis-2020-218359
Annals of the Rheumatic Diseases 2021;80:626-631.
Objective Juvenile idiopathic arthritis (JIA) is the most common type of arthritis among children, but a few studies have investigated the contribution of rare variants to JIA. In this study, we aimed to identify rare coding variants associated with JIA for the genome-wide landscape.
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
Xianyong Yin, Kwangwoo Kim, Hiroyuki Suetsugu, So-Young Bang, Leilei Wen, Masaru Koido, Eunji Ha, Lu Liu, Yuma Sakamoto, Sungsin Jo, Rui-Xue Leng, Nao Otomo, Viktoryia Laurynenka, Young-Chang Kwon, Yujun Sheng, Nobuhiko Sugano, Mi Yeong Hwang, Weiran Li, Masaya Mukai, Kyungheon Yoon, Minglong Cai, Kazuyoshi Ishigaki, Won Tae Chung, He Huang, Daisuke Takahashi, Shin-Seok Lee, Mengwei Wang, Kohei Karino, Seung-Cheol Shim, Xiaodong Zheng, Tomoya Miyamura, Young Mo Kang, Dongqing Ye, Junichi Nakamura, Chang-Hee Suh, Yuanjia Tang, Goro Motomura, Yong-Beom Park, Huihua Ding, Takeshi Kuroda, Jung-Yoon Choe, Chengxu Li, Hiroaki Niiro, Youngho Park, Changbing Shen, Takeshi Miyamoto, Ga-Young Ahn, Wenmin Fei, Tsutomu Takeuchi, Jung-Min Shin, Keke Li, Yasushi Kawaguchi, Yeon-Kyung Lee, Yongfei Wang, Koichi Amano, Dae Jin Park, Wanling Yang, Yoshifumi Tada, Ken Yamaji, Masato Shimizu, Takashi Atsumi, Akari Suzuki, Takayuki Sumida, Yukinori Okada, Koichi Matsuda, Keitaro Matsuo, Yuta Kochi, Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, Leah C Kottyan, Matthew T Weirauch, Sreeja Parameswaran, Shruti Eswar, Hanan Salim, Xiaoting Chen, Kazuhiko Yamamoto, John B Harley, Koichiro Ohmura, Tae-Hwan Kim, Sen Yang, Takuaki Yamamoto, Bong-Jo Kim, Nan Shen, Shiro Ikegawa, Hye-Soon Lee, Xuejun Zhang, Chikashi Terao, Yong Cui, Sang-Cheol Bae
doi : 10.1136/annrheumdis-2020-219209
Annals of the Rheumatic Diseases 2021;80:632-640.
Objective Systemic lupus erythematosus (SLE), an autoimmune disorder, has been associated with nearly 100 susceptibility loci. Nevertheless, these loci only partially explain SLE heritability and their putative causal variants are rarely prioritised, which make challenging to elucidate disease biology. To detect new SLE loci and causal variants, we performed the largest genome-wide meta-analysis for SLE in East Asian populations.
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
Dinesh Khanna, Suiyuan Huang, Celia J F Lin, Cathie Spino
doi : 10.1136/annrheumdis-2020-219100
Annals of the Rheumatic Diseases 2021;80:641-650.
Objectives American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in diffuse systemic sclerosis. ACR-CRISS is a weighted score and includes five core set measures: modified Rodnan skin score, FVC% predicted, health assessment questionnaire–disability index, and patient and clinician global assessments.
Anti-centromere antibodies target centromere–kinetochore macrocomplex: a comprehensive autoantigen profiling
Nobuhiko Kajio, Masaru Takeshita, Katsuya Suzuki, Yukari Kaneda, Humitsugu Yamane, Kazuhiro Ikeura, Hidekazu Sato, Shin Kato, Hiroyuki Shimizu, Kazuyuki Tsunoda, Tsutomu Takeuchi
doi : 10.1136/annrheumdis-2020-218881
Annals of the Rheumatic Diseases 2021;80:651-659.
Objectives Anti-centromere antibodies (ACAs) are detected in patients with various autoimmune diseases such as Sj?gren’s syndrome (SS), systemic sclerosis (SSc) and primary biliary cholangitis (PBC). However, the targeted antigens of ACAs are not fully elucidated despite the accumulating understanding of the molecular structure of the centromere. The aim of this study was to comprehensively reveal the autoantigenicity of centromere proteins.
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic
Naomi Serling-Boyd, Kristin M D’Silva, Tiffany YT Hsu, Rachel Wallwork, Xiaoqing Fu, Ellen M Gravallese, April M Jorge, Yuqing Zhang, Hyon Choi, Jeffrey A Sparks, Zachary S Wallace
doi : 10.1136/annrheumdis-2020-219279
Annals of the Rheumatic Diseases 2021;80:660-666.
Objective In earlier studies, patients with rheumatic and musculoskeletal disease (RMD) who got infected with COVID-19 had a higher risk of mechanical ventilation than comparators. We sought to determine COVID-19 outcomes among patients with RMD 6?months into the pandemic.
Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints
Cleo Rogier, Bastiaan T van Dijk, Elisabeth Brouwer, Pascal H P de Jong, Annette H M van der Helm-van Mil
doi : 10.1136/annrheumdis-2020-219513
Annals of the Rheumatic Diseases 2021;80:668-669.
What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern
Philipp Gauckler, Erica L Bettac, Manfred Nairz, Christina Duftner, Anna K Luger, Markus Stein, David Wanner, Barbara C B?ckle, Martin Tiefenthaler, Peter Schratzberger, Hannes Neuwirt, Lukas Harasser, Gert Mayer, Andreas Kronbichler
doi : 10.1136/annrheumdis-2020-219212
Annals of the Rheumatic Diseases 2021;80:669-671.
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
Aron Hjalti Bjornsson, Gerdur Grondal, Mar Kristjansson, Thorunn Jonsdottir, Thorvardur Jon Love, Bjorn Gudbjornsson
doi : 10.1136/annrheumdis-2020-219564
Annals of the Rheumatic Diseases 2021;80:671-672.
Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: a national study
Jasvinder A Singh, John D Cleveland
doi : 10.1136/annrheumdis-2020-218386
Annals of the Rheumatic Diseases 2021;80:672-675.
The virtual fishbowl: bringing back dynamic debates to medical conferences
Felix Muehlensiepen, Johanna Mucke, Martin Krusche, Sandra Kurkowski, Gerlinde Bendzuck, Ina Koetter, Vanessa Lemarié, Manuel Grahammer, Martin Heinze, Hendrik Schulze-Koops, Johannes Knitza
doi : 10.1136/annrheumdis-2020-219552
Annals of the Rheumatic Diseases 2021;80:675-676.
COVID-19 in patients with rheumatological diseases treated with anti-TNF
Carlos Antunes Brito, José Gerardo Paiva, Fernando Nunes Pimentel, Rosinete Santos Guimar?es, Mariana Ribeiro Moreira
doi : 10.1136/annrheumdis-2020-218171
Annals of the Rheumatic Diseases 2021;80:e62.
Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences
Jun Zhao, Rongrong Pang, Jian Wu, Yanju Guo, Yang Yang, Libo Zhang, Xinyi Xia
doi : 10.1136/annrheumdis-2020-218183
Annals of the Rheumatic Diseases 2021;80:e63.
Response to: ‘COVID-19 in patients with rheumatological diseases treated with Anti-TNF’ by Brito et al and ‘Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences’ by Zhao et al
Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace
doi : 10.1136/annrheumdis-2020-218196
Annals of the Rheumatic Diseases 2021;80:e64.
Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic
Pedro Santos-Moreno, Josefina Chavez-Chavez, Sandra Milena Hern?ndez-Zambrano, Diana Patricia Rivera-Triana, Ruth Alexandra Castiblanco-Monta?ez, Anggie Aza, Diana Buitrago-Garcia, Laura Villarreal, Adriana Rojas-Villarraga
doi : 10.1136/annrheumdis-2020-218165
Annals of the Rheumatic Diseases 2021;80:e65.
Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
doi : 10.1136/annrheumdis-2020-218193
Annals of the Rheumatic Diseases 2021;80:e66.
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko
doi : 10.1136/annrheumdis-2020-218075
Annals of the Rheumatic Diseases 2021;80:e67.
Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
Sara Monti, Carlomaurizio Montecucco
doi : 10.1136/annrheumdis-2020-218148
Annals of the Rheumatic Diseases 2021;80:e68.
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun
doi : 10.1136/annrheumdis-2020-218154
Annals of the Rheumatic Diseases 2021;80:e69.
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-218173
Annals of the Rheumatic Diseases 2021;80:e70.
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India
Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, Akshat Pandey, Nikhil Gupta, Rahul Jain, Shashank Akerkar, Parthajit Das, Rajkiran Dudam, Naval Mendiratta, Bimlesh Dhar Pandey, Mithun CB, Bharat K Singh, Sharath Kumar, Nilesh Nolkha, Shriyanka Jain, Somya Jain, Ashish Sharma, Durga Prasanna Misra
doi : 10.1136/annrheumdis-2020-218013
Annals of the Rheumatic Diseases 2021;80:e71.
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-218146
Annals of the Rheumatic Diseases 2021;80:e72.
Presence of antiphospholipid antibodies in COVID-19: a case series study
Luis M Amezcua-Guerra, Gustavo Rojas-Velasco, Malinalli Brianza-Padilla, Armando V?zquez-Rangel, Ricardo M?rquez-Velasco, Francisco Baranda-Tovar, Rashidi Springall, Hector Gonzalez-Pacheco, Yaneli Ju?rez-Vicu?a, Claudia Tavera-Alonso, Fausto Sanchez-Mu?oz, Marisol Hern?ndez-Salas
doi : 10.1136/annrheumdis-2020-218100
Annals of the Rheumatic Diseases 2021;80:e73.
Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al
Alexis Mathian, Marc Pineton De Chambrun, Alain Combes, Zahir Amoura
doi : 10.1136/annrheumdis-2020-218145
Annals of the Rheumatic Diseases 2021;80:e74.
Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients
Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali
doi : 10.1136/annrheumdis-2020-218068
Annals of the Rheumatic Diseases 2021;80:e75.
Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al
Vasco C Rom?o, Ana Rita Cruz-Machado, Jo?o Eurico Fonseca
doi : 10.1136/annrheumdis-2020-218175
Annals of the Rheumatic Diseases 2021;80:e76.
Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus
Yasushi Kondo, Yuko Kaneko, Tatsuhiro Oshige, Hiroyuki Fukui, Shuntaro Saito, Mikio Okayama, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Koichi Fukunaga, Tsutomu Takeuchi
doi : 10.1136/annrheumdis-2020-218157
Annals of the Rheumatic Diseases 2021;80:e77.
Response to: ‘Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus’ by Kondo et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-218176
Annals of the Rheumatic Diseases 2021;80:e78.
Correspondence on ‘Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab’
Francesco Messina, Francesca Pampaloni, Stefano Piaserico
doi : 10.1136/annrheumdis-2020-218029
Annals of the Rheumatic Diseases 2021;80:e79.
Response to: ‘Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina et al
Pierre-Marie Duret, Lionel Spielmann, Laurent Messer
doi : 10.1136/annrheumdis-2020-218147
Annals of the Rheumatic Diseases 2021;80:e80.
Correction: Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren’s syndrome
doi : 10.1136/ard.2011.154013.corr1
Annals of the Rheumatic Diseases 2021;80:e81.
Correction: Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, shame-controlled pilot trial
doi : 10.1136/annrheumdis-2020-217872corr1
Annals of the Rheumatic Diseases 2021;80:e82.
Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
doi : 10.1136/annrheumdis-2020-218510corr1
Annals of the Rheumatic Diseases 2021;80:e83.
Correction: Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
doi : 10.1136/annrheumdis-2018-213403corr1
Annals of the Rheumatic Diseases 2021;80:e84.
